Protillion Biosciences is pioneering a transformative approach to therapeutic protein discovery and optimization through the use of high-throughput protein technologies. Their platform enables the simultaneous quantitative characterization of protein candidates at an unprecedented scale, allowing for the discovery of therapeutic molecules with exceptional specificity, finely tuned affinities—including ultra-high affinities—and manufacturability. This advancement addresses the historical lag in protein analysis speed and throughput compared to DNA data generation, particularly in the context of next-generation sequencing (NGS). By leveraging a library encoding protein-based drug candidates and a high-throughput protein analysis chip, Protillion is positioned to revolutionize the field of drug discovery.

In addition to their innovative protein analysis capabilities, Protillion employs advanced machine learning techniques to enhance drug discovery processes. This combination of computational approaches with rigorous wet experimentation allows for effective training and validation of their models, significantly improving throughput and miniaturization in the discovery pipeline. The company aims to replicate the transformative impact that NGS had on biology and medicine, signaling a new era in protein discovery that promises to deliver more effective therapeutic candidates to the market.

United States

Protillion Biosciences is a Stanford University spinout commercializing disruptive technology for therapeutic antibody and binder discovery. We have developed an entirely novel, powerful and high-throughput protein display platform designed to revolutionize traditional approaches to the design and development of protein-based drugs.

Protillion Biosciences

Company Details